Retrophin, Inc. (RTRX): Price and Financial Metrics


Retrophin, Inc. (RTRX)

Today's Latest Price: $24.25 USD

0.11 (-0.45%)

Updated Nov 18 4:15pm

Add RTRX to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 240 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

RTRX Stock Summary

  • With a price/sales ratio of 6.38, Retrophin Inc has a higher such ratio than 78.92% of stocks in our set.
  • As for revenue growth, note that RTRX's revenue has grown 12.53% over the past 12 months; that beats the revenue growth of 73.24% of US companies in our set.
  • Retrophin Inc's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is -9.03%, greater than the shareholder yield of merely 24.95% of stocks in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Retrophin Inc are ATNX, KPTI, QUIK, RDUS, and FBIO.
  • Visit RTRX's SEC page to see the company's official filings. To visit the company's web site, go to www.retrophin.com.

RTRX Stock Price Chart Interactive Chart >

Price chart for RTRX

RTRX Price/Volume Stats

Current price $24.25 52-week high $24.96
Prev. close $24.36 52-week low $8.98
Day low $24.04 Volume 378,900
Day high $24.74 Avg. volume 412,277
50-day MA $20.67 Dividend yield N/A
200-day MA $17.78 Market Cap 1.24B

Retrophin, Inc. (RTRX) Company Bio


Retrophin focuses on the development, acquisition, and commercialization of therapies for the treatment of serious, catastrophic, or rare diseases, including focal segmental glomerulosclerosis (FSGS), pantothenate kinase-associated neurodegeneration (PKAN), infantile spasms, nephrotic syndrome and others. The company was founded in 2011 and is based in San Diego, California.


RTRX Latest News Stream


Event/Time News Detail
Loading, please wait...

RTRX Latest Social Stream


Loading social stream, please wait...

View Full RTRX Social Stream

Latest RTRX News From Around the Web

Below are the latest news stories about Retrophin Inc that investors may wish to consider to help them evaluate RTRX as an investment opportunity.

Retrophin enrolls patients for the study of sparsentan in IgA nephropathy

Retrophin (RTRX) announced that the first 280 patients have been enrolled in the pivotal Phase 3 PROTECT Study evaluating the safety and efficacy of sparsentan in IgA nephropathy.Topline efficacy data from the 36-week proteinuria endpoint analysis are expected in Q3 2021. "As a result of achieving this important enrollment milestone...

Seeking Alpha | September 21, 2020

BofA bullish on Retrophin, sees 56% upside

BofA analyst Scott Puckhaber has initiated coverage on Retrophin ([[RTRX]] +3.9%) with a Buy rating and $30 (56% upside) price target.Topline data from two Phase 3 clinical trials evaluating lead candidate sparsentan are expected in H2 2021 in two kidney indications, ahead of previous guidance of H1 2022 mentioned in its Q2...

Seeking Alpha | August 24, 2020

Retrophin to Present at Upcoming Investor Conferences

SAN DIEGO, Aug. 03, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that Company management will participate in the following…

GlobeNewswire | August 3, 2020

Retrophin Reports Second Quarter 2020 Financial Results

Enrollment ahead of schedule in Phase 3 PROTECT Study of sparsentan in IgAN; topline proteinuria data from both pivotal studies in FSGS and IgAN now…

GlobeNewswire | July 30, 2020

Retrophin (RTRX) Reports Q2 Loss, Misses Revenue Estimates

Retrophin (RTRX) delivered earnings and revenue surprises of 0.00% and -0.14%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | July 30, 2020

Read More 'RTRX' Stories Here

RTRX Price Returns

1-mo 15.37%
3-mo 25.39%
6-mo 54.61%
1-year 77.14%
3-year 12.27%
5-year 9.28%
YTD 70.77%
2019 -37.25%
2018 7.40%
2017 11.30%
2016 -1.87%
2015 57.60%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 1.0215 seconds.